Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024

miodrag ignjatovic/E+ via Getty ImagesWe previously covered Abbott Laboratories (NYSE:NYSE:ABT) in October 2023 as a Buy, discussing Ozempic/Mounjaro as the driving force surrounding the increased adoption for ABT's glucose monitoring equipment, FreeStyle Libre. The same had been observed in the company's Diabetes Medical Devices and Nutrition segment performances over the past few quarters, further contributing to its profitable growth trend then. By now, it is apparent that ABT has exceeded expectatio ...